UTHR vs HLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
UTHR · United Therapeutics$554.73 ▼ 0.78%
HLN · Haleon$9.07 ▲ 0.22%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- UTHR +16.2%
- HLN -4.3%
Head to head
| Metric | UTHR | HLN |
|---|---|---|
| Price | $554.73 | $9.07 |
| Change today | ▼ 0.78% | ▲ 0.22% |
| Market cap | $23.63B | $39.76B |
| Return, 3 months | +8.2% | -10.7% |
| Return, year to date | +13.8% | -8.5% |
| Return, 1 year | +16.8% | -6.3% |
| P/E (TTM) | 20.9 | 19.1 |
| P/B | 3.8 | 1.9 |
| P/E percentile vs own 5y | 96th | 15th |
| Dividend yield | – | 2.09% |
| Revenue growth (YoY, latest qtr) | +4.1% | -0.3% |
| Net profit growth (YoY) | -23.6% | +3,071.4% |
| Gross margin | 86.3% | 65.0% |
| Operating margin | 39.4% | 21.4% |
| Net margin | 38.6% | 14.6% |
| Return on equity | 19.1% | 10.0% |
| Analyst target vs. price | +23.0% | +21.3% |
| Analyst buy share | 79% | 100% |
| RSI (14) | 42 | 44 |
| 30-day volatility | 31.9% | 51.7% |
| Max drawdown, 1 year | -20.9% | -22.4% |
| Trend read | Mixed | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HLN is the largest of the group by market value.
- UTHR has returned the most over the past year.
- HLN carries the lowest trailing P/E.
- UTHR is growing revenue fastest.
- UTHR keeps the most profit per dollar of sales.
- UTHR has been the calmest stock over the last 30 days.